Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1996 Apr;34(4):848–852. doi: 10.1128/jcm.34.4.848-852.1996

Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

A Espinel-Ingroff 1, M Pfaller 1, M E Erwin 1, R N Jones 1
PMCID: PMC228904  PMID: 8815095

Abstract

An interlaboratory evaluation (two centers) of the Etest method was conducted for testing the antifungal susceptibilities of yeasts. The MICs of amphotericin B, fluconazole, flucytosine, itraconazole, and ketoconazole were determined for 83 isolates of Candida spp., Cryptococcus neoformans, and Torulopsis glabrata. Two buffered (phosphate buffer) culture media were evaluated: solidified RPMI 1640 medium with 2% glucose and Casitone agar. MIC endpoints were determined after both 24 and 48 h of incubation at 35 degrees C. Analysis of 3,420 MICs demonstrated higher interlaboratory agreement (percentage of MIC pairs within a 2-dilution range) with Casitone medium than with RPMI 1640 medium when testing amphotericin B (84 to 90% versus 1 to 4%), itraconazole (87% versus 63 to 74%), and ketoconazole (94 to 96% versus 88 to 90%). In contrast, better interlaboratory reproducibility was determined between fluconazole MIC pairs when RPMI 1640 medium rather than Casitone medium was used (96 to 98% versus 77 to 90%). Comparison of the flucytosine MICs obtained with RPMI 1640 medium revealed greater than 80% reproducibility. The study suggests the potential value of the Etest as a convenient alternative method for testing the susceptibilities of yeasts. It also indicates the need for further optimization of medium formulations and MIC endpoint criteria to improve interlaboratory agreement.

Full Text

The Full Text of this article is available as a PDF (185.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anaissie E. J., Bodey G. P., Rinaldi M. G. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 1989 Apr;8(4):323–330. doi: 10.1007/BF01963467. [DOI] [PubMed] [Google Scholar]
  2. Anaissie E., Paetznick V., Bodey G. P. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother. 1991 Aug;35(8):1641–1646. doi: 10.1128/aac.35.8.1641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beck-Sagué C., Jarvis W. R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993 May;167(5):1247–1251. doi: 10.1093/infdis/167.5.1247. [DOI] [PubMed] [Google Scholar]
  4. Block E. R., Jennings A. E., Bennett J. E. 5-fluorocytosine resistance in Cryptococcus neoformans. Antimicrob Agents Chemother. 1973 Jun;3(6):649–656. doi: 10.1128/aac.3.6.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brass C., Shainhouse J. Z., Stevens D. A. Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother. 1979 Jun;15(6):763–768. doi: 10.1128/aac.15.6.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colombo A. L., Barchiesi F., McGough D. A., Rinaldi M. G. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol. 1995 Mar;33(3):535–540. doi: 10.1128/jcm.33.3.535-540.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dupont B., Graybill J. R., Armstrong D., Laroche R., Touzé J. E., Wheat L. J. Fungal infections in AIDS patients. J Med Vet Mycol. 1992;30 (Suppl 1):19–28. doi: 10.1080/02681219280000731. [DOI] [PubMed] [Google Scholar]
  8. Espinel-Ingroff A., Dawson K., Pfaller M., Anaissie E., Breslin B., Dixon D., Fothergill A., Paetznick V., Peter J., Rinaldi M. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995 Feb;39(2):314–319. doi: 10.1128/aac.39.2.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Espinel-Ingroff A. Etest for antifungal susceptibility testing of yeasts. Diagn Microbiol Infect Dis. 1994 Aug;19(4):217–220. doi: 10.1016/0732-8893(94)90034-5. [DOI] [PubMed] [Google Scholar]
  10. Espinel-Ingroff A., Kerkering T. M., Goldson P. R., Shadomy S. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1991 Jun;29(6):1089–1094. doi: 10.1128/jcm.29.6.1089-1094.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Espinel-Ingroff A., Kish C. W., Jr, Kerkering T. M., Fromtling R. A., Bartizal K., Galgiani J. N., Villareal K., Pfaller M. A., Gerarden T., Rinaldi M. G. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1992 Dec;30(12):3138–3145. doi: 10.1128/jcm.30.12.3138-3145.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Espinel-Ingroff A., Rodríguez-Tudela J. L., Martínez-Suárez J. V. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans. J Clin Microbiol. 1995 Dec;33(12):3154–3158. doi: 10.1128/jcm.33.12.3154-3158.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Espinel-Ingroff A., Steele-Moore L., Galgiani J. N. Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. Diagn Microbiol Infect Dis. 1994 Oct;20(2):81–86. doi: 10.1016/0732-8893(94)90096-5. [DOI] [PubMed] [Google Scholar]
  14. Fromtling R. A., Galgiani J. N., Pfaller M. A., Espinel-Ingroff A., Bartizal K. F., Bartlett M. S., Body B. A., Frey C., Hall G., Roberts G. D. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother. 1993 Jan;37(1):39–45. doi: 10.1128/aac.37.1.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ghannoum M. A., Ibrahim A. S., Fu Y., Shafiq M. C., Edwards J. E., Jr, Criddle R. S. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol. 1992 Nov;30(11):2881–2886. doi: 10.1128/jcm.30.11.2881-2886.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. KEYE J. D., Jr, MAGEE W. E. Fungal diseases in a general hospital; a study of 88 patients. Am J Clin Pathol. 1956 Nov;26(11):1235–1253. doi: 10.1093/ajcp/26.11.1235. [DOI] [PubMed] [Google Scholar]
  17. Paya C. V. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993 May;16(5):677–688. doi: 10.1093/clind/16.5.677. [DOI] [PubMed] [Google Scholar]
  18. Pfaller M. A., Bale M., Buschelman B., Lancaster M., Espinel-Ingroff A., Rex J. H., Rinaldi M. G., Cooper C. R., McGinnis M. R. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 1995 May;33(5):1104–1107. doi: 10.1128/jcm.33.5.1104-1107.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pfaller M. A., Barry A. L. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 1994 Aug;32(8):1992–1996. doi: 10.1128/jcm.32.8.1992-1996.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pfaller M. A., Messer S. A., Coffmann S. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870. J Clin Microbiol. 1995 May;33(5):1094–1097. doi: 10.1128/jcm.33.5.1094-1097.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pfaller M. A., Rinaldi M. G., Galgiani J. N., Bartlett M. S., Body B. A., Espinel-Ingroff A., Fromtling R. A., Hall G. S., Hughes C. E., Odds F. C. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother. 1990 Sep;34(9):1648–1654. doi: 10.1128/aac.34.9.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Polak A., Scholer H. J. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy. 1975;21(3-4):113–130. doi: 10.1159/000221854. [DOI] [PubMed] [Google Scholar]
  23. Redding S., Smith J., Farinacci G., Rinaldi M., Fothergill A., Rhine-Chalberg J., Pfaller M. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994 Feb;18(2):240–242. doi: 10.1093/clinids/18.2.240. [DOI] [PubMed] [Google Scholar]
  24. Rex J. H., Cooper C. R., Jr, Merz W. G., Galgiani J. N., Anaissie E. J. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother. 1995 Apr;39(4):906–909. doi: 10.1128/aac.39.4.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rodriguez-Tudela J. L., Martinez-Suarez J. V. Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrob Agents Chemother. 1994 Jan;38(1):45–48. doi: 10.1128/aac.38.1.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sewell D. L., Pfaller M. A., Barry A. L. Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole. J Clin Microbiol. 1994 Sep;32(9):2099–2102. doi: 10.1128/jcm.32.9.2099-2102.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. States B., Segal S. Levels of gamma-glutamyltranspeptidase in cultured skin fibroblasts from cystinotics and normals. Life Sci. 1980 Nov 24;27(21):1985–1990. doi: 10.1016/0024-3205(80)90419-1. [DOI] [PubMed] [Google Scholar]
  28. TORACK R. M. Fungus infections associated with antibiotic and steroid therapy. Am J Med. 1957 Jun;22(6):872–882. doi: 10.1016/0002-9343(57)90023-2. [DOI] [PubMed] [Google Scholar]
  29. Wey S. B., Mori M., Pfaller M. A., Woolson R. F., Wenzel R. P. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988 Dec;148(12):2642–2645. doi: 10.1001/archinte.148.12.2642. [DOI] [PubMed] [Google Scholar]
  30. Wingard J. R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995 Jan;20(1):115–125. doi: 10.1093/clinids/20.1.115. [DOI] [PubMed] [Google Scholar]
  31. ZIMMERMAN L. E. Candida and Aspergillus endocarditis, with comments on the role of antibiotics in dissemination of fungus disease. AMA Arch Pathol. 1950 Nov;50(5):591–605. [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES